Summary
The understanding of vaccine-induced immune responses in adults and infants is limited. Current vaccination schedules for infants are frequently debated. Especially, the relationship among the timing, the frequency of the dosing, and the generation of an immunological memory are debated. Vaccine antigen-induced cytokine responses to vaccinations given in infancy are of particular interest because little is known about cellular responses in this age, and the information available is based on antibody responses. Pharmacogenomics is ideally suited to study cellular responses related to immune response; in addition, toxicity, inflammation, apoptosis, stress, and oncogenesis can be monitored, since the expression of thousands of genes can be measured in a single experiment.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Food and Drug Administration (FDA), Center for Biologics Evaluation and Research Washington D.C. Preliminary guidelines for the manufacture and evaluation of DNA vaccines. (1996) Docket 96N–0400.
Pilaro, A.M., and Serabian, M.A. (1999) Preclinical development strategies for novel gene therapeutic products. Toxicol. Pathol. 27, 4–7.
Fauci, A.S. (2001) Infectious diseases: considerations for the 21st century. Clin. Infect. Dis. 32, 675–685.
Pauwels, R., van der Straeten, M., Platteau, B., and Bazin, H. (1983) The non-specific enhancement of allergy. In vivo effects of Bordetella pertussis vaccine on IgE synthesis. Allergy. 38, 239–246.
Dhiman, N., Bornilla, R., O'Kane, D.J., and Poland, G.A. (2001) Gene expression microarrays: a 21st century tool for directed vaccine design. Vaccine. 20, 22–30.
Regnstrüm, K., Ragnarsson, E.G.E., Rydell, N., Sjüholm, I., and Artursson, P. (2002) Tetanus antigen modulates the gene expression profile of aluminum phosphate adjuvant in spleen lymphocytes in vivo. Pharmacogenom. J. 2, 57–64.
Regnstrüm, K., Ragnarsson, E.G.E., and Artursson, P. (2003) Gene expression after vaccination of mice with formulations of diphtheria- or tetanus toxoid and different adjuvants: arrays identify shared immune response genes and vaccine-specific genes in spleen lymphocytes. Vaccine. 21, 2307–2317.
Regnstrüm, K., Ragnarsson, E.G.E., Küping-Hüggård, M., Torstensson, L., Nyblom, N., and Artursson, P. (2003) PEI–a potent, but not harmless, mucosal immunostimulator of mixed T-helper cell response and FasL mediated cell death in mice. Gene Ther. 10, 1575–1583.
Regnstrüm, K., Ragnarsson, E.G.E., Fryknäs, M., Küping-Hüggård, M., and Artursson, P. (2006) Gene expression profiles in mouse lung tissue after administration of two cationic polymers used for non-viral gene delivery. Pharm. Res. 23, 475–482.
Regnstrüm, K., and Burgess, D. (2006) Pharmacogenomics and its potential impact on drug and formulation development. Crit. Rev. Ther. Drug Carrier Syst. 22, 465–492.
Slonim, D.K. (2001) Transcriptional profiling in cancer: the clinical pathway to pharmacogenomics. Pharmacogenomics. 2, 123–136.
Lesko, L.J., and Woodcock, J. (2004) Translation of pharmacogenomics and pharmacogenetics: a regulatory perspective. Nat. Rev. Drug Discov. 3, 763–769.
Food and Drug Administration (FDA). Guidance for industry, pharmacogenomics data submissions. Available at: http://www.fda.gov/cber/gdlns/pharmdtasub.htm. Accessed March 31, 2005.
Olin, P., Rasmussen, F., Gustafsson, L., Hallander, H.O., and Heijbel, H. (1997) Randomised controlled trial of two-component, three-component, and five-component acellular pertussis vaccines compared with whole-cell pertussis vaccine. Ad Hoc Group for the Study of Pertussis Vaccines. Lancet. 350, 1569–1577.
Gustafsson, L., Hallander, H.O., Olin, P., Reizenstein, E., Storsaeter, J. (1996) A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine. N. Engl. J. Med. 334, 349–355.
Odent, M.R., Culpin, E.E., and Kimel, T. (1994) Pertussis vaccination and asthma: is there a link? JAMA. 272, 929–931.
Kemp, T., Pearce, N., Fitzharris, P., et al. (1997) Is infant immunization a risk factor for childhood asthma or allergy? Epidemiology. 8, 678–680.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Humana Press, a part of Springer Science+Business Media, LLC
About this protocol
Cite this protocol
Nilsson, L.J., Regnström, K.J. (2008). Pharmacogenomics in the Evaluation of Efficacy and Adverse Events During Clinical Development of Vaccines. In: Yan, Q. (eds) Pharmacogenomics in Drug Discovery and Development. Methods in Molecular Biology™, vol 448. Humana Press. https://doi.org/10.1007/978-1-59745-205-2_17
Download citation
DOI: https://doi.org/10.1007/978-1-59745-205-2_17
Publisher Name: Humana Press
Print ISBN: 978-1-58829-887-4
Online ISBN: 978-1-59745-205-2
eBook Packages: Springer Protocols